A follow-up showed that OVA PsVs could elicit therapeutic responses to OVA-expressing tumours in mice, as well as generating stronger OVA-specific CD8+ T cell responses than DNA delivered by other delivery methods31, indicating its utility as a therapeutic vaccine delivery system. This evidence concerns the gene CD8A and neoplasm.